Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917974 | 0.91 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL4907896 | 0.86 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL3080455 | 0.85 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL3086555 | 0.83 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL3080459 | 0.83 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL4908643 | 0.83 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL4885391 | 0.82 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL4906459 | 0.81 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL4911542 | 0.81 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4911560 | 0.78 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
| US-20100234439-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234438-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234439-A1 | THERAPEUTIC AGENTS | NLN, GPR119, GRIK5 | CNR1 185/4885CNR2 148/4885 |
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | CNR1 597/4885CNR2 480/4885 |
| US-20100234438-A1 | THERAPEUTIC AGENTS | NLN, GPR119, GRIK5 | CNR1 185/4885CNR2 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.